No reason it should trade above .04. That's where it was pre-FDA trial approval, and the company still is years away from the first penny of revenue from any kind of stem therapy. Big money knows how many years it takes to actual application, that's why they have not invested a dime in actc. Pre-FDA there were zero revenues, today there are zero revenues. The only difference is that now actc is in the very earliest phase/timeline of FDA approved trials, and that don't mean squat to the market since it takes years to market a therapy if no one else beats actc to the endline (like, STEM, or the many other trials recently approved that may or may not have anything to do with stem cells, but are targeting AMD and SMD).